Dyadic licenses fungal platforms to Proliant for recombinant albumin; up to $1.5M milestones + profit share

DYADIC INTERNATIONAL INC

Dyadic and Proliant Health and Biologicals partner to commercialize animal-free recombinant human serum albumin.
Dyadic to receive up to $1.5M in milestone payments plus a share of profits from product sales.
First product launch expected in the first half of 2025, targeting the ~$6B serum albumin market.
Proliant will use Dyadic's fungal microbial expression platforms for production.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.